| Literature DB >> 32671676 |
Bernadett Bettina Patai1, Nora Peterfy2, Noemi Szakacs3, Zoltan Sapi4, Judit Reka Hetthessy5.
Abstract
Although papillary endothelial hyperplasia may occur at almost any site, one of the most common sites is the hand. It is generally regarded as a reactive vascular proliferation i.e. exuberant form of organizing thrombus. Diagnosis of Masson tumor can be challenging due to its close clinical, radiological and even histopathological resemblance to angiosarcoma. We present seven cases of Masson tumor of the hand; wanting to reveal its nature using new vascular markers and discuss the treatment options and expected outcomes, present clinical and radiological features that may aid diagnosis and also offer treatment plans. A multicenter retrospective study was performed between January 2014 and November 2019. Immunohistochemical stains of Glut1, WT1, ERG, CD31 and alpha smooth muscle actin (ASMA) were performed on each cases. We found seven cases during the examined period. 4 out of 7 cases were women. All lesions occurred in the hands. 3 out of 7 cases appeared in a previously present vascular malformation. All cases were treated with surgical excision and the diagnosis of papillary endothelial hyperplasia was made by histology. Pre-operative testing (radiograph/MRI/US/fine needle aspiration biopsy) did not suggest the diagnosis of Masson tumor; however, aspiration cytology could rule out malignancy. The proliferative endothelial cells proved to be Glut1 negative and WT1 positive and the accompanying pericytic cells were ASMA positive in all cases. Though Masson tumor is a rare vascular lesion in the hand among other vascular tumors, it should be considered in the differential diagnostics even in the case of previously existing vascular malformation. WT1 positivity of the endothelial cells and the accompanying pericytic cells raises the question whether the initially reactive endothelial proliferation may transform into a true benign vascular tumor.Entities:
Keywords: Hand; IPEH; Intravascular papillary endothelial hyperplasia; Masson tumor; Soft tissue lesion; Vascular malformation; Vascular tumor
Mesh:
Substances:
Year: 2020 PMID: 32671676 PMCID: PMC7471200 DOI: 10.1007/s12253-020-00838-8
Source DB: PubMed Journal: Pathol Oncol Res ISSN: 1219-4956 Impact factor: 3.201
Summary of patient age, gender, location of lesion, appearance of the lesion, duration of symptoms, previous treatments, radiological examinations, surgical care, postoperative complications, recurrences, pathological markers
| Clinicopathology | |||||||
|---|---|---|---|---|---|---|---|
| Patient number | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| AGE (YEARS OLD) | 26 | 30 | 24 | 36 | 71 | 31 | 61 |
| GENDER | female | female | male | male | female | male | female |
| SIDE, location | 2nd metacarpo-phalangeal jointl, palmar side of the right hand | Proximal phalanx of the left thumb | 1st metacarpo-phalangeal joint, palmar side of the left hand | Distal phalanx of the right thumb | Distal phalanx of the left ring finger, dorsoradial side | Distal phalanx of the left ring finger, dorsal side | Middle phalanx of the right ring finger, palmar side |
| HOW LONG HAS THE PATIENT HAD A VASCULAR LESION | since childhood | for 4 months | since childhood | for 6 months | for 24 months | for 24 months | for 2 days |
| LENGTH OF COMPLAINTS | 6 months | 4 months | 8 months | 2 months | 24 moths | 24 moths | for 1 week |
| Previous treatmenTs | sclerotization 1x | – | sclerotization 1x, surgical treatment 5x | surgery 1x | – | – | – |
| Symptoms | palpable mass, grew in size; tenderness to palpation | palpable mass, grew in size; tenderness to palpation, limited range of motion | palpable mass, grew in size; tenderness to palpation, limited range of motion | discomfort, palpable mass, tenderness | discomfort, palpable mass | palpable mass, changing in size on occasion; no local tenderness | discomfort, palpable mass, tenderness |
| Pre-operative diagnosis | haemangioma | ganglion haemangioma | haemangioma | not obtained | not obtained | not obtained | not obtained |
| Diagnosis bases on | prev. Histopathological diagnosis | US FNAB | MRI | clinical examination | clinical examination | clinical examination | clinical examination |
| De novo / secondary | previous haemangioma | de novo | previous haemangioma | previously histological diagnosis was not performed | de novo | de novo | de novo |
| Surgical care | marginal excision | marginal excision | marginal excision | marginal excision | marginal excision | marginal excision | marginal excision |
| Complications | – | – | transient paraesthesia around the 1st digital nerve, which resolved | – | – | – | – |
| Lenegth of follow up (Months) | 12 | 12 | 3 | 6 | 3 | 6 | 66 |
| Recurrence | – | – | – | – | – | – | – |
| functional results | hand function improved (circulation, sensation, motion = CSM, in order) | hand function improved,CSM in order | hand function improved, transient | hand function improved, (CSM in order) | hand function improved, (CSM in order) | hand function improved, (CSM in order) | hand functions improved, (CSM in order) |
| Pathological markers (Glut1, WT1, CD31, ERG, ASMA) | GLUT1 negative; WT1, CD31, ERG, ASMA positive | GLUT1 negative; WT1, CD31, ERG, ASMA positive | GLUT1 negative; WT1, CD31, ERG, ASMA positive | GLUT1 negative; WT1, CD31, ERG, ASMA positive | GLUT1 negative; WT1, CD31, ERG, ASMA positive | GLUT1 negative; WT1, CD31, ERG, ASMA positive | GLUT1 negative; WT1, CD31, ERG, ASMA positive |
Fig. 1a From left to right: T2-weighted anterio-posterior MRI image of Patient No 1., Surgical excision, Post-operative function. b T2-weight AP MRI of Patient No 3. c Surgical excision performed for Patient No 6., result at 6-months follow-up
Fig. 2a, Characteristic overview of Masson tumor: dilated vessel with clotted blood and papillary endothelial proliferation. b, Papillae are composed of a single layer of endothelium with collagenized core. c, Hemosiderin deposits in connective tissue could be observed in almost all cases
Fig. 3Strong cytoplasmic CD31 (a) and nuclear ERG (b) positivity could be detected on endothelial cells, but it is also evident that other cellular components are present in the tumor. (Immunohistochemical stain with CD31 and ERG)
Fig. 4Glut1 is negative in endothelial cells (arrows), only red blood cells are positive (arrowheads) (a). WT1 is clearly positive on endothelial cells (b), while ASMA displays pericytes (c). (Immunohistochemical stain with Glut1, WT1, and ASMA)